Cystine

The Fanion™ Kitchen Gadget Offers Relief From Irritating Onion-Cutting, Slicing, and Dicing Tears During Food Prep

Retrieved on: 
Wednesday, November 1, 2023
Taste, Yellow onion, Onion, Atmosphere, Cystine, Methionine, Red onion, White onion, Sweet onion, Tears, Vegetable, Shallot, Fast food

ATLANTA, Nov. 1, 2023 /PRNewswire-PRWeb/ -- Fanion, a small family business dedicated to innovations in kitchen gadgetry, has announced the official launch of their first product, The Fanion™ is a convenient, battery-powered kitchen fan that eliminates painful tears when chopping, cutting, slicing, and dicing onions and other eye-irritating vegetables like shallots and peppers by dispersing those devastating fumes away from our sensitive eyes. This cute kitchen direct-to-consumer product is now being sold on MyFanion.com for $29.95 and can be shipped anywhere in the continental U.S.

Key Points: 
  • I tried EVERYTHING – including all of those viral 'hacks' you see on Instagram and TikTok to stop those onion tears.
  • Glenn Smith, Founder, The Fanion™
    "Nobody wants to cry in the kitchen during food prep, which is a time for family bonding in our household," said Glenn Smith, the Founder of The Fanion™ .
  • I tried EVERYTHING – including all of those viral 'hacks' you see on Instagram and TikTok to stop those onion tears.
  • Order in early November and The Fanion™ can be a part of your Thanksgiving meal prep.

AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting

Retrieved on: 
Thursday, May 18, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Tissue, Central nervous system, Gene, Comorbidity, Gastrointestinal disease, Health care, Food, Aes, Food and Drug Administration, Skin, Liver, Brain, SOC, Stem cell, Beery, Cystinosis, Metabolism, AVRO, Cystine, Clinical trial, Patient, Standard of care, Blood, Cell, Cysteamine, HSC, MRCP, FDA, FFPM, Safety, Neuropathology, Society, DSM-IV codes, MHRA, Disease, Pharmaceutical industry, Vaccine, Medical imaging

These data are being presented at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles, California, on May 18, 2023.

Key Points: 
  • These data are being presented at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles, California, on May 18, 2023.
  • “We are excited about moving this investigational gene therapy closer to patients.”
    In addition to the data presented, the Company also announced positive and productive meetings with the U.K.
  • Preliminary data from this trial suggest that this HSC gene therapy is well tolerated, with no AEs related to the drug product to date.
  • An oral presentation by Dr. Cherqui on these data, “Phase 1/2 Clinical Trial of Autologous Hematopoietic Stem and Progenitor Cell Gene Therapy for Cystinosis,” will occur today at 3:45 PM PT in the session Metabolic, Storage, Endocrine, Liver and Gastrointestinal Disease II of the ASGCT Annual Meeting.

AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 11, 2023
Health, Stem Cells, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, GMP, VCN, Gaucher's disease, Central nervous system, University, Gene, Clinical trial, Glycogen, MPS II, Skin, Glycogen storage disease type II, MPS, CNS, Hunter syndrome, Gaucher, AVRO, HSPC, Patient, Physician, Annual general meeting, Cell, CFO, American Society of Gene and Cell Therapy, HSC, Innovation, UOM, FDA, Enzyme replacement therapy, Syndrome, Research, Safety, Society, GI, Cystine, DSM-IV codes, MHRA, Pharmaceutical industry, Medical device, Cryptocurrency

(Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the first quarter ended March 31, 2023, and provided a business update.

Key Points: 
  • (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the first quarter ended March 31, 2023, and provided a business update.
  • Plan to initiate Guard3, a global registrational Phase 2/3 trial for GD3, in the second half of 2023, subject to regulatory alignment.
  • AVROBIO reported a net loss of $25.0 million for the first quarter of 2023 as compared to a net loss of $29.8 million for the comparable period in 2022.
  • Based on AVROBIO’s current operating plan, AVROBIO expects its cash and cash equivalents as of March 31, 2023, will enable AVROBIO to fund its operating expenses and capital expenditure requirements into the first quarter of 2024.

American Kidney Fund Will Host Cystinosis Camp as Part of National Virtual Camp for Children and Teens with Kidney Disease

Retrieved on: 
Monday, May 8, 2023
Camper, Partnership, American Kidney Fund, Kidney failure, AKF, Horizon Therapeutics, Kidney, Cystinosis, National Virtual Observatory, Cystine, Kidney disease, Disease, Pharmaceutical industry

ROCKVILLE, Md., May 08, 2023 (GLOBE NEWSWIRE) -- This fall, the American Kidney Fund will be offering special programming specifically for children with cystinosis during its much-loved national virtual camp for children and teens with kidney disease.

Key Points: 
  • ROCKVILLE, Md., May 08, 2023 (GLOBE NEWSWIRE) -- This fall, the American Kidney Fund will be offering special programming specifically for children with cystinosis during its much-loved national virtual camp for children and teens with kidney disease.
  • The camp provides an opportunity for children and teens with kidney disease to participate in fun activities, as well as share their experiences with other children who are also battling kidney disease.
  • Cystinosis is a rare genetic condition that occurs in about 1 in 100,000-200,000 children and is not widely known or understood.
  • The campers will participate in the regularly scheduled National Virtual Camp and will be invited to join two one-hour networking programs exclusively for children and teens with cystinosis.

AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 23, 2023
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, GMP, Tissue, VCN, University of California, San Diego Performance-Based Skills Assessment, Gaucher's disease, Enteropathy, University, Safety, Health care, Food, CMC, Aes, Clinical trial, MPS II, Skin, Glycogen storage disease, Cerebrospinal fluid, MPS, CNS, IDS, Cystinosis, AVRO, ERT, HSPC, Patient, Physician, Risk, Medicines and Healthcare products Regulatory Agency, Liver, CSF, HSC, UOM, FDA, Syndrome, Enzyme replacement therapy, Lymphadenopathy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hunter syndrome, GI, Cystine, DSM-IV codes, MHRA, Disease, Pharmaceutical industry, Vaccine, Gaucher

(Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2022 and provided a business update.

Key Points: 
  • (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2022 and provided a business update.
  • “2022 was a transformative year for AVROBIO, topped in December with a robust clinical and regulatory update for our Gaucher disease program.
  • Safety data to date from GD1 and GD3 patients indicate no adverse events (AEs) related to drug product.
  • No major chemistry, manufacturing and controls (CMC) changes are anticipated for AVROBIO’s plato® gene therapy platform as the company prepares to enter a registrational trial for GD3.

Potato Protein Market worth $144 million by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, March 17, 2023
Taste, Smell, Starch, Scoular, Food, Methionine, Drink, Lysine, Food industry, Soybean, Marketing, Roquette Frères, Fertilizer, Livestock, Dry, Par value, Cysteine, Slice, Carbon, Dicarboxylic acid, USD, NASS, Meat, Pesticide, Cattle, Yogurt, National Agricultural Statistics Service, Growth, Region, Transport, Cystine, Flour, Dietary supplement, Nature, Form

CHICAGO, March 17, 2023 /PRNewswire/ -- The Potato Protein Market is projected to reach USD 144 million by 2028 from USD 105 million by 2022, at a CAGR of 5.4% from 2022 to 2028 according to a report published by MarketsandMarkets™.

Key Points: 
  • CHICAGO, March 17, 2023 /PRNewswire/ -- The Potato Protein Market is projected to reach USD 144 million by 2028 from USD 105 million by 2022, at a CAGR of 5.4% from 2022 to 2028 according to a report published by MarketsandMarkets™.
  • However, in the food industry, due to its high instability after isolation by thermal coagulation of the potato juice, potato protein finds very limited usage.
  • After the starch production, the remaining juice is gently dried, and the brownish-grey powder leftover remains organic potato protein.
  • The North American potato protein market is a growing industry driven by increasing demand for plant-based protein and the health benefits of potato protein.

Potato Protein Market worth $144 million by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, March 17, 2023
Taste, Smell, Starch, Scoular, Food, Methionine, Drink, Lysine, Food industry, Soybean, Marketing, Roquette Frères, Fertilizer, Livestock, Dry, Par value, Cysteine, Slice, Carbon, Dicarboxylic acid, USD, NASS, Meat, Pesticide, Cattle, Yogurt, National Agricultural Statistics Service, Growth, Region, Transport, Cystine, Flour, Dietary supplement, Nature, Form

CHICAGO, March 17, 2023 /PRNewswire/ -- The Potato Protein Market is projected to reach USD 144 million by 2028 from USD 105 million by 2022, at a CAGR of 5.4% from 2022 to 2028 according to a report published by MarketsandMarkets™.

Key Points: 
  • CHICAGO, March 17, 2023 /PRNewswire/ -- The Potato Protein Market is projected to reach USD 144 million by 2028 from USD 105 million by 2022, at a CAGR of 5.4% from 2022 to 2028 according to a report published by MarketsandMarkets™.
  • However, in the food industry, due to its high instability after isolation by thermal coagulation of the potato juice, potato protein finds very limited usage.
  • After the starch production, the remaining juice is gently dried, and the brownish-grey powder leftover remains organic potato protein.
  • The North American potato protein market is a growing industry driven by increasing demand for plant-based protein and the health benefits of potato protein.

Biosimilar Interleukins Global Market Report 2022: Rising Prevalence of Autoimmune Conditions Spurring Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 8, 2022
Health, Pharmaceutical, Acquisition, Distribution, Pharmacy, Johns Hopkins University, Degenerative disease, Growth, Application, Population, IBD, IL-5, Cancer, Sanofi, Asthma, Rheumatoid arthritis, IL-6, Interleukin 17, Interleukin, Psoriasis, Cystine, Prevalence, Cell, Autoimmune disease, Inflammatory bowel disease, Generic drug, Vaccine

The "Biosimilar Interleukins Global Market Report 2022: By Type, By Application, By Distribution" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimilar Interleukins Global Market Report 2022: By Type, By Application, By Distribution" report has been added to ResearchAndMarkets.com's offering.
  • The increasing prevalence of autoimmune diseases such as psoriasis and rheumatoid arthritis is expected to boost the growth of the interleukin biosimilars market in the forecast period.
  • Therefore, the increasing prevalence of autoimmune diseases is increasing the demand for the biosimilar interleukins market and is expected to drive the growth of the market.
  • Synthorx, Inc. is a US-based biotechnology company focused on developing interleukins for people suffering from cancer and autoimmune disorders.

Travere Therapeutics Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 5, 2022
GAAP, SIMD, HCU, Safety, Caregiver, Irbesartan, Travers Tool, Life, Annual general meeting, Risk, Investor, EGFR, CMA, Mission statement, NASDAQ, Company, Kidney, Patient, FDA, SG, Regulation of tobacco by the U.S. Food and Drug Administration, New Drug Application, PROTECT, Disease, SAN, Therapy, Heart Protection Study, U.S. Securities and Exchange Commission, Society, Private Securities Litigation Reform Act, Immunoglobulin A, Union, Proteinuria, NDA, Research, Security (finance), Cystinuria, International, R, MAA, Vifor Pharma, Acquisition, COVID-19, Table, Maintenance, GLOBE, Food, Trial of the century, Review, Webcast, Income tax, Patent, Cystine, Form 10-K, Pharmaceutical industry, Fine chemical, Lithium, Bank, FSGS, IgA nephropathy

SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2022 financial results and provided a corporate update.

Key Points: 
  • SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2022 financial results and provided a corporate update.
  • Total other expense, net, for the first quarter of 2022 was $9.8 million, compared to $6.0 million for the same period in 2021.
  • ET to discuss company updates as well as first quarter 2022 financial results.
  • The Company believes that these non-GAAP financial measures are helpful in understanding its past financial performance and potential future results.

AllianceRx Walgreens Prime Relaunches Exclusive Partnership for the Distribution of Cystaran® (cysteamine ophthalmic solution) 0.44%

Retrieved on: 
Tuesday, March 22, 2022
Pancreas, Risk, Induced coma, Organization, Pharmacy, Headache, Degenerative disease, Partnership, Research, Eyelid, Program, Leadiant Biosciences, Patient, Cystinosis, Food, Tissue, Pharmacist, Contact lens, Senior, Light, Quality of life, Regulation of tobacco by the U.S. Food and Drug Administration, Muscle, Cystine, Mark (given name), FDA, Hospital, Pharmaceutical industry, Health insurance, Walgreens, Cysteamine

ORLANDO, Fla., March 22, 2022 /PRNewswire/ -- Leadiant Biosciences, Inc. has partnered with AllianceRx Walgreens Prime – one of the largest specialty and home delivery pharmacies in the U.S. – to be the exclusive specialty pharmacy and clinical support provider for its rare disease drug Cystaran.

Key Points: 
  • "We have had a nearly decade-long partnership which is why Leadiant Biosciences has entrusted us as the exclusive specialty pharmacy to support the relaunch of Cystaran.
  • As an exclusive partner, AllianceRx Walgreens Prime is able to offer end-to-end solutions for Leadiant Biosciences and Cystaran patients, according to James.
  • Leadiant Biosciences recently relaunched the brand with revised packaging through the exclusive agreement with AllianceRx Walgreens Prime.
  • "Leadiant Biosciences is pleased to continue its long-standing partnership with AllianceRx Walgreens Prime," says Mike Minarich, Chief Executive Officer, Leadiant Biosciences.